Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zampilimab in kidney transplant recipients with chronic allograft injury
NCT04335578Phase 2Terminated
- Sponsor
- UCB
- Start
- Oct 2019
- Primary completion
- May 2022
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 4
01
Overview
A Phase 2 trial of Zampilimab in chronic allograft injury (CAI), sponsored by UCB. Started Oct 2019; status: terminated.
02
Drugs
Zampilimab
03
Conditions
chronic allograft injury (CAI)
Beyond the preview
Go deeper on NCT04335578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04335578.